Simplifying antiretroviral therapy

AIDS Reader

Volumn 14, Issue 7, 2004, Pages

  Tapper, Michael L ^a,b,c   Flexner, Charles ^d   Eron, Joseph J ^e   Molina, Jean Michel ^f  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Division of Infectious Diseases   (United States)

^c LENOX HILL HOSPITAL   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Adherence; Antiretroviral therapy; Dosing, once daily; HIV AIDS

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; FATTY LIVER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; LACTIC ACIDOSIS; LIFESTYLE; LYMPHOCYTE COUNT; PANCREATITIS; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PILL; PRACTICE GUIDELINE; REVIEW; SUSTAINED RELEASE PREPARATION; TREATMENT OUTCOME; VIRUS LOAD; VIRUS REPLICATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HALF-LIFE; HIV INFECTIONS; HUMANS; PATIENT COMPLIANCE; TREATMENT OUTCOME;

EID: 3242702195     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report 2002;14. Available at: http://www.cdc.gov/hiv/stats/hasrlink.htm. Accessed February 26, 2004.
2. Furrer H, Egger M, Opravil M, et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. N Engl J Med. 1999;340:1301-1306.
3. Weverling GJ, Mocroft A, Ledergerber B, et al. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group. Lancet. 1999;353:1293-1298.
4. Schneider MM, Borleffs JC, Stolk RP, et al. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy. Lancet. 1999;353:201-203.
5. Low-Beer S, Yip B, O'Shaughnessy MV, et al. Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr. 2000;23:360-361.
6. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
7. Bartlett JA, DeMasi R, Quinn J, et al. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS. 2001;15:1369-1377.
8. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. March 23, 2004. Available at: http://AIDSinfo.nih.gov. Accessed March 30, 2004.
9. Bass D, Smith MF. HIV patients prefer once-daily regimens. Presented at the XIV International AIDS Conference; July 7-12, 2002; Barcelona, Spain. Abstract MoPeB3290.
10. Barditch-Crovo P, Deeks SG, Collier A, et al. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother. 2001;45:2733-2739.
11. Cheer SM, Goa KL. Stavudine once daily. Drugs. 2002;62:2667-2674.
12. Kilby JM, Sfakianos G, Gizzi N, et al. Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults. Antimicrob Agents Chemother. 2000;44:2672-2678.
13. Sham HL, Kempf DJ, Molla A, et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother. 1998;42:3218-3224.
14. Wood R, Trepo C, Livrozet JM, et al. Enhancement of pharmacokinetic parameters of amprenavir when combined with low dose ritonavir (APV 600 mg/RTV 100 mg bid) and preliminary efficacy results. AIDS. 2000;14(suppl 4):S98. Abstract P283.
15. Hugen PW, Burger DM, ter Hofstede HJ, et al. Dose-finding study of a once-daily indinavir/ritonavir regimen. J Acquir Immune Defic Syndr. 2000;25:236-245.
16. Wang LH, Begley J, Feng J, et al. Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing. Presented at the XIV International AIDS Conference; July 7-12, 2002; Barcelona, Spain. Abstract TuPeB4546.
17. van Leth F, Hassink E, Phanuphak P, et al. Results of the 2NN study: a randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, together with stavudine and lamivudine. Presented at the 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston. Abstract 176.
18. DeJesus E, Grinsztejn B, Gough K, et al. Comparable antiviral efficacy and safety of lamivudine administered 300 mg once daily versus 150 mg bid both in combination with zidovudine (300 mg bid) and efavirenz (600 mg qd) in HIV-1 infected, antiretroviral-naive adults: EPV20001. Presented at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2002; San Diego. Abstract H-161.
19. Pollard R, Ive P, Farthing C, et al. Stavudine XR vs stavudine IR as part of potent antiretroviral combination therapy: 24-week safety and antiviral efficacy (BMS 099). Presented at the 9th Conference on Retroviruses and Opportunistic Infections; February 24-28, 2002; Seattle. Abstract 411-W.
20. Staszewski S, Gallant JE, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine when used in combination with lamivudine and efavirenz in antiretroviral naive patients: 96-week preliminary interim results. Presented at the 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston. Abstract 564b.
21. Eron JJ, Feinberg J, Kessler HA, et al. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial. J Infect Dis. 2004;189:265-272.
22. Schurmann D, Gathe J, Sanne J, Wood R. Efficacy and safety of GW433908/ritonavir once daily in therapy-naive subjects, 48 week results: the SOLO study. Presented at the 6th International Congress on Drug Therapy in HIV Infection; November 17-21, 2002; Glasgow, Scotland. Abstract PL14.4.
23. Squires K, Thiry A, Giordano M. Atazanavir QD and efavirenz QD with fixed-dose ZDV + 3TC: comparison of antiviral efficacy and safety through week 24. Presented at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30, 2002; San Diego. Abstract 1078.
24. Molina JM, Ferchal F, Rancinan C, et al. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients. J Infect Dis. 2000;182:599-602.
25. Cahn P, Raffi F, Saag M, et al. Virologic efficacy and patterns of resistance mutations in ART-naive patients receiving combination therapy with daily emtricitabine compared to twice-daily stavudine in a randomized, double-blind, multicenter clinical trial. Presented at the 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston. Abstract 606.
26. Molina JM, Ferchal F, Rancinan C, et al. Once-daily combination of emtricitabine, didanosine, and efavirenz vs continued PI-based HAART in HIV-infected adults with undetectable plasma HIV-RNA: 48-week results of a prospective randomized multicenter trial (ALIZE-ANRS 99). Presented at the 10th Conference on Retroviruses and Opportunistic Infections; February 10-14, 2003; Boston. Abstract 551.
27. Gathe J, Podzamczer D, Johnson M, et al. Once-daily vs twice-daily lopinavir/ritonavir in antiretroviral-naive patients: 48-week results. Presented at the 11th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2004; San Francisco. Abstract 570.
28. Gallant JE, Rodriguez AE, Weinberg W, et al. Early non-response to tenofovir DF (TDF) + abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz (EFV) + ABC and 3TC: ESS30009. Presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 14-17, 2003; Chicago. Abstract 1722a.
29. Farthing C, Khanlou H, Yeh V. Early virologic failure in a pilot study evaluating the efficacy of abacavir, lamivudine and tenofovir in the treatment naive HIV-infected patients. Presented at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment; July 13-16, 2003; Paris. Abstract 43.
30. Landman R, Peytavin G, Descamps D, et al. Low genetic barrier to resistance is a possible cause of early virologic failures in once-daily regimen of abacavir, lamivudine, and tenofovir: the Tonus study. Presented at the 11th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2004; San Francisco. Abstract 52.
31. Jemsek J, Hutcherson P, Harper E. Poor virologic responses and early emergence of resistance in treatment naive, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF. Presented at the 11th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2004; San Francisco. Abstract 51.